Research Info

Home /SIMULTANEOUS MICRORNA-612 ...
Title SIMULTANEOUS MICRORNA-612 RESTORATION AND 5-FU TREATMENT INHIBIT THE GROWTH AND MIGRATION OF HUMAN PANC-1 PANCREATIC CANCER CELLS
Type JournalPaper
Keywords miR-612, PANC-1, 5-FU, pancreatic cancer, electroporation
Abstract Despite the recent advances in the treatment of other cancers, the 5-year survival rate of pancreatic cancer remains under 9 %. Chemotherapy and surgical resection are the most common therapy methods. The regulatory role of microRNAs in different types of cancer has given them therapeutic importance. miR-612 has been downregulated in colorectal, bladder, liver, and some other types of cancer and could be considered a tumor-suppressor miRNA. 5-FU is one of the most common chemotherapeutic agents used in pancreatic cancer treatment, which is used in multiple drug regimens and combinatorial therapy methods. The aim of this study is the evaluation of miR-612 restoration in the PANC-1 cell line and using the tumor-suppressive effect of it in combination with 5-FU on cell growth and migration. MiR-612 mimic was transfected to PANC-1 cells through electroporation. Following the transfection, expression levels of miR-612 and BAX, BCL-2, Caspase-3, MMP9, and PD-L1 genes were measured by qRT-PCR. MTT assay was used to determine the cytotoxicity of miR-612 and 5-FU on PANC-1 cell viability. To confirm MTT results and to evaluate the quantitative effect of apoptosis induction flow cytometry test was used and in order to confirm apoptosis test results and cell cycle arrest evaluation DAPI staining and cell, cycle tests were conducted, respectively. Finally, to assess the inhibitory effect of miR-612 in combination with 5-FU on migration and growth wound healing and colony formation assays were used, respectively. Results demon-strated that miR-612 alongside 5-FU has an important role in the inhibition of migration and growth and also apoptosis induction in PANC-1 cells and could be considered as a supporting agent of chemotherapy and a novel therapeutic modality in pancreatic cancer treatment.
Researchers Behzad Baradaran (Not In First Six Researchers), Vahid Khaze Shahgoli (Not In First Six Researchers), Elham Baghbani (Not In First Six Researchers), Ziba Lotfi (Not In First Six Researchers), (Fifth Researcher), Sahar Safaee1 (Fourth Researcher), Amir Baghbanzadeh (Third Researcher), Reza Mohammadzadeh (Second Researcher), Darya Javadrashid (First Researcher)